NRx Pharma Starts Treating Patients With Inhaled Aviptadil In Collaborative COVID-19 Trial - NRX Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals Inc NRXP and Quantum Leap Healthcare Collaborative have begun treating patients with inhaled Zyesami (Aviptadil) in the I-SPY COVID Trial.
The I-SPY COVID Trial utilizes Quantum Leap's adaptive platform trial design methodology, which focuses on the efficient assessment of multiple investigational agents simultaneously.
The trial's objective is to screen a variety of promising agents to identify agents that have a high impact on reducing mortality and the need for and duration of mechanical ventilation.
Zyesami has demonstrated a statistically significant increase in the likelihood of patients being alive and free of respiratory failure at 60 days in a Phase 2b/3 trial in posthoc analyses.
NRx Pharmaceuticals recently submitted an Emergency Use Authorization request to the FDA for Zyesami to treat critical COVID-19 patients with respiratory failure.
Price Action: NRXP shares are up 5.4% at $12.13 during the market session on the last check Monday.